Johnson & Johnson (JNJ)
| Market Cap | 561.61B +57.9% |
| Revenue (ttm) | 94.19B +5.1% |
| Net Income | 26.80B +71.1% |
| EPS | 11.03 +71.3% |
| Shares Out | 2.41B |
| PE Ratio | 21.13 |
| Forward PE | 20.21 |
| Dividend | $5.20 (2.23%) |
| Ex-Dividend Date | Feb 24, 2026 |
| Volume | 9,345,967 |
| Open | 231.50 |
| Previous Close | 230.75 |
| Day's Range | 230.48 - 235.20 |
| 52-Week Range | 141.50 - 235.20 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 227.29 (-2.49%) |
| Earnings Date | Jan 21, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $227.29, which is a decrease of -2.49% from the latest price.
News
What's Behind The 50% Surge In JNJ Stock?
In the nearly nine months spanning from May 2025 to February 2026, Johnson & Johnson (JNJ)'s stock experienced a remarkable 52% increase, driven by improved earnings, significant product achievements,...
Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland
World's #1 Selling Contact Lens Brand ACUVUE®*1 Brings Pioneering Innovation For Astigmatic Patients With Presbyopia, Providing Visual Clarity And Comfort**2
Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, 2026. Management will participate in a Firesi...
Ariel Focus Fund Q4 2025 Portfolio Review
Barrick Mining Corporation's solid liquidity supports its commitment to shareholder returns, reflected in increased share repurchases and a raise in its quarterly dividend. Johnson & Johnson's perform...
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over
Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations
AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen a...
US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy
A U.S. district judge on Thursday dismissed a lawsuit alleging Johnson & Johnson committed fraud by repeatedly attempting to use a shell company's bankruptcy to resolve tens of thousands of lawsuits c...
This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks
Susan Bao's large-cap JPMorgan fund has outperformed the S&P 500 over many years. She's bullish on stocks, focused on bargains.
Johnson & Johnson: Strong Momentum Heading Into 2026
Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales resilience. Their deal with the Trump Administration eliminates tariffs in exchange ...
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth in...
Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help mor...
Best Dividend Kings: January 2026
Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%, though 14 Kings outperformed the index. 2026 began strongly for Dividend Kings, up 4.66% through January 23...
Johnson & Johnson is doing 'great things for patients,' CFO says
Johnson & Johnson executive vice president and CFO Joseph Wolk discusses the company's performance and President Donald Trump's healthcare agenda on 'The Claman Countdown.' #fox #media #breakingnews #...
Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi
PENSACOLA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- A U.S. District Court Special Master in the talc multidistrict litigation (MDL) against Johnson & Johnson (J&J) entered an Opinion, reaffirming that ...
Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth
Johnson & Johnson's MedTech segment saw its worldwide operational sales grow 5.4% year over year in 2025, reaching about $33.8 billion, the company said in a Wednesday (Jan. 21) earnings release. The ...
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates
Johnson & Johnson (NYSE:JNJ) on Wednesday reported better-than-expected fourth-quarter earnings.
OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings
Johnson & Johnson (JNJ) posted better-than-expected earnings but still traded to the downside. Diane King Hall points to Stelara as the cause.
J&J expects to hit $100 billion in revenue next year after new strategy pays off
Johnson & Johnson sees revenue grow 9% in the fourth quarter, amid strength in its cancer drugs.
Johnson & Johnson forecasts 2026 profit above Wall Street estimates
Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of Wall Street estimates, even when including a hit of "hundreds of millions of dollars" from the drug pricing deal it signed with...
J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales
The healthcare company's forecast for 2026 tops Wall Street's expectations.
Johnson & Johnson reports Q4 and Full-Year 2025 results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. “2025 was a catapult year for Johnson & Johnson, fueled by the strong...
Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson (NYSE: JNJ) will release earnings for the fourth quarter before the opening bell on Wednesday, Jan. 21.
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings
Johnson & Johnson (NYSE: JNJ) will release earnings for the fourth quarter before the opening bell on Wednesday, Jan. 21.
Is Johnson & Johnson A Dividend Stock, Or Something Else?
Healthcare may be entering early mean reversion, but much of Johnson & Johnson's valuation recovery has already occurred. Post-Kenvue, JNJ is a higher-growth, less dividend-centric business, changing ...